May 6, 2022 08:00AM
May 2, 2022 08:00AM
Apr 25, 2022 01:15PM
Oct 26, 2020 08:00AM
Oct 5, 2020 08:00AM
Aug 5, 2020 08:30AM
Jun 15, 2020 08:00AM Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes
May 21, 2020 06:13PM
May 19, 2020 08:00AM
Apr 15, 2020 05:04PM
Mar 26, 2020 08:00AM
Dec 30, 2019 08:06AM
Dec 30, 2019 08:05AM
Dec 30, 2019 08:02AM Urovant Sciences (UROV) Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance
Dec 30, 2019 08:00AM
Dec 20, 2019 08:00AM
Dec 12, 2019 08:00AM
Nov 22, 2019 09:00AM
Nov 8, 2019 07:00AM
Sep 27, 2019 08:00AM
Sep 6, 2019 09:00AM Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance
Sep 6, 2019 03:01AM
Jul 30, 2019 08:00AM
Jun 6, 2019 07:55PM
May 10, 2019 08:00AM
May 2, 2019 08:00AM
May 1, 2019 08:00AM
Jan 30, 2019 10:15PM Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Sep 19, 2018 08:00AM
Sep 19, 2018 08:00AM
Sep 12, 2018 08:00AM
Aug 31, 2018 09:30AM
Jul 25, 2018 08:00AM
Jun 27, 2018 02:30PM
Jun 23, 2018 09:00AM Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson’s Disease and Movement Disorders Congress
Jun 12, 2018 05:00PM
Jun 1, 2018 02:00PM
May 17, 2018 09:51AM
May 16, 2018 08:23AM
May 2, 2018 08:00AM
Apr 25, 2018 08:30AM
Apr 20, 2018 11:34AM Sunovion Announces Health Canada Approval of Latuda® (lurasidone HCl) to Treat Adolescents (13 to 17 years of age) with Bipolar Depression
Apr 3, 2018 08:00AM
Mar 30, 2018 08:00AM
Mar 6, 2018 03:37PM
Jan 29, 2018 04:30PM
Dec 5, 2017 08:48PM
Nov 29, 2017 08:00AM
Nov 10, 2017 10:30AM Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD
Oct 31, 2017 08:00AM

328,887 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All